This article is more than 5 years old. Information may no longer be current.

Icon's inflammation therapy for cataract surgery enters phase 3 trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Icon Bioscience Inc. announced its IBI-10090 has reached phase 3 study as a sustained-release therapy for inflammation associated with cataract surgery.

IBI-10090 dispenses a long-acting, biodegradable formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered following surgery, according to the company’s press release.

In the previous phase involving 170 patients and three dosing strengths, IBI-10090 was found safe and effective, with patients achieving anterior chamber cell clearing at day 8.

Phase 3 is expected to enroll 390 patients across 28 locations in the U.S. The dose-ranging study employs the two lower doses used in the prior phase 2/3 study. Patient enrollment began in December 2013 with a goal of completion in late 2014.